[Innovative antibody-therapies for malignant lymphomas]

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Non-Hodgkin s lymphoma (NHL) is a group of lymphoproliferative disorders with increasing incidence, predominantly affecting the elderly.
• Conventional therapies like chemotherapy have limitations in this demographic due to toxicity and side effects.
• There is a need for novel treatment strategies with improved safety profiles.

Purpose of the Study:

• To summarize the application of novel immunotherapies in Non-Hodgkin s lymphoma (NHL).
• To review recent clinical trial results for these emerging therapies.
• To emphasize practical aspects and indications for clinical use.

Main Methods:

• Review of current literature and clinical trial data on immunotherapies for NHL.
• Focus on monoclonal antibodies (e.g., rituximab, alemtuzumab) and radio-immunotherapies.
• Analysis of treatment outcomes, safety profiles, and clinical applicability.

Main Results:

• Monoclonal antibody therapy, particularly rituximab, is established for NHL treatment.
• Alemtuzumab shows promise for chronic lymphatic leukemia and T-cell lymphomas.
• Radio-immunotherapies are emerging, with promising results in advanced indolent lymphomas.

Conclusions:

• Novel immunotherapies represent a significant advancement in NHL treatment, offering reduced toxicity.
• Further investigation is ongoing for their use in high-grade lymphomas and as first-line therapy.
• These therapies are becoming increasingly relevant in clinical practice for managing NHL.